Intra-cisterna-magna bevacizumab injection (ICM-BI) reproduces pathological alterations of cerebral small vessel diseases

Xinmei Kang,Xiaotao Su,Tiemei Li,Shisi Wang,Huipeng Huang,Yuxin Liu,Chunyi Li,Xiaohui Deng,Mengyan Hu,Tingting Lu,Lei Wei,Wei Cai,Zhengqi Lu
DOI: https://doi.org/10.1177/0271678x241295856
2024-10-27
Journal of Cerebral Blood Flow & Metabolism
Abstract:Journal of Cerebral Blood Flow &Metabolism, Ahead of Print. General modeling strategies for sporadic cerebral small blood vessel diseases (CSVDs) include limiting blood stream in large blood vessels and inducing systemic hypertension, in which small blood vessel deficit is either a secondary or concomitant pathology. In the current study, we introduce that intra-cisterna-magna Bevacizumab injection (ICM-BI) directly causes cerebral small blood vessel injury by neutralizing VEGF-A, the indispensable growth factor for angiogenesis. ICM-BI reproduces neuro-functional impairment, tight junction loss, cerebral micro-bleeds (CMBs), amyloid peptide accumulation, neuronal injury, white matter loss, and glial cell activation, which are common manifestations of sporadic CSVDs. Compared with existing CSVD models, small blood vessel injury is more prominent in the ICM-BI brain. Moreover, no significant alteration in large blood vessels or peripheral organs after ICM-BI is recorded. We thus propose that ICM-BI is a neat, economic and applicable methodology to establish murine sporadic CSVD model.
neurosciences,endocrinology & metabolism,hematology
What problem does this paper attempt to address?